Responses in refractory hairy cell leukemia to a recombinant immunotoxin

Blood

Volumn 94, Issue 10, 1999, Pages 3340-3348

  Kreitman, Robert J ^b   Wilson, Wyndham H ^b   Robbins, David ^b   Margulies, Inger ^b   Stetler Stevenson, Maryalice ^b   Waldmann, Thomas A ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; IMMUNOTOXIN;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; DOSE RESPONSE; DRUG EFFECT; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECOMBINANT DNA TECHNOLOGY; REMISSION; TARGET CELL;

EID: 0033571548     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.10.3340.422k19_3340_3348     Document Type: Article

References (57)

1. Huston JS, Levinson D, Mudgett-Hunter M, Tai M-s, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H: Protein engineering of antibody binding sites: Recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879, 1988
2. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M: Single-chain antigen-binding proteins. Science 242:423, 1988
3. Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D. Kostakoglu L, Schlom J, Larson SM: Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 36:586, 1995
4. Yamaizumi M, Mekada E, Uchida T, Okada Y: One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15:245, 1978
5. Kreitman RJ, Chaudhary VK, Kozak RW, FitzGerald DJP, Waldmann TA, Pastan I: Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood 80:2344, 1992
6. Uchiyama TA, Broder S, Waldmann TA: A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. 1. Production of anti-Tac monoclonal antibody and distribution of Tac(+)cells. J Immunol 126:1393, 1981
7. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, Fitz-Gerald DJ, Pastan I: A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394, 1989
8. Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJP, Pastan I: Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 83:426, 1994
9. Kreitman RJ, Chaudhary VK, Waldmann T, Willingham MC, FitzGerald DJ, Pastan I: The recombinant immunotoxin anti-Tac(Fv)-Pseuodomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. Proc Natl Acad Sci USA 87:8291, 1990
10. Kreitman RJ, Chaudhary VK, Waldmann TA, Hanchard B, Cranston B, FitzGerald DJP, Pastan I: Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 7:553, 1993
11. Saito T, Kreitman RJ, Hanada S-i, Makino T, Utsunomiya A, Sumizawa T, Arima T, Chang CN, Hudson D, Pastan I, Akiyama S-i: Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor. Cancer Res 54:1059, 1994
12. Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ, Pastan I: Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconj Chem 4:112, 1993
13. Chiron MF, Fryling CM, FitzGerald DJ: Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 269:18167, 1994
14. Fryling C, Ogata M, FitzGerald D: Characterization of a cellular protease that cleaves Pseudomonas exotoxin. Infect Immun 60:497, 1992
15. 280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem 267:25396, 1992
16. Kreitman RJ, Pastan I: Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307:29, 1995
17. Hessler JL, Kreitman RJ: An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 36:14577, 1997
18. Theuer C, Kasturi S, Pastan I: Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry 33:5894, 1994
19. Theuer CP, Buchner J, FitzGerald D, Pastan I: The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc Natl Acad Sci USA 90:7774, 1993
20. Carroll SF, Collier RJ: Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem 262:8707, 1987
21. Brinkmann U, Brinkmann E, Gallo M, Pastan I: Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSEI. Proc Natl Acad Sci USA 92:10427, 1995
22. Kreitman RJ, Pastan I: Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol 6:297, 1995
23. Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticuloendotheliosis. Blood 13:609, 1958
24. Cheson BD, Martin A: Clinical trials in hairy cell leukemia. Current status and future directions. Ann Intern Med 106:871, 1987 (erratum 107:604, 1987)
25. Catovsky D, Matutes E, Talavera JG, O'Connor NTJ, Johnson SA, Emmett E, Corbett L, Swansbury J: Long term results with 2′deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 14:109, 1994 (suppl 1)
26. Saven A, Burian C, Koziol JA, Piro LD: Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918, 1998
27. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 13:974, 1995
28. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, Tallman M, Annino L, Connors J, Coiffier B, Lauria F: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: A report of 979 patients. J Clin Oncol 16:3007, 1998
29. Carbone A, Reato G, Di Celle PF, Lauria F, Foa R: Disease eradication in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine [letter]. Leukemia 8:2019, 1994
30. Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, Doyen C, Mineur P, Glorieux P, Driesschaert P, Sokal E, Martat P, Michaux JL: A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153, 1994
31. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I: Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin. Nat Med 2:350, 1996
32. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79:2547, 1992
33. 486IL-2 in hematological cancers. Cancer Res 53:3930, 1993
34. 486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma 14:257, 1994
35. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blattler WA, Epstein CL, Nadler LM: Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726, 1993
36. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blattler WA, Epstein CL, Nadler LM: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81:2263, 1993
37. Hartmann F, Horak EM, Garmestani K, Wu CC, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL, Waldmann TA: Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody Bi-212-anti-Tac. Cancer Res 54:4362, 1994
38. Schmid M, Porzsolt F: Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leuk Lymphoma 17:401, 1995
39. Muller-Werdan U, Engelmann H, Werdan K: Cardiodepression by tumor necrosis factor-alpha. Eur Cytokine Netw 9:689, 1998
40. McLaughlin P, GrilloLopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, BenceBruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825, 1998
41. Frankel AE, Hall PD, McLain C, Safa AR, Tagge EP, Kreitman RJ: Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconj Chem 9:490, 1998
42. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schon G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E: A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89:403, 1997
43. Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramilo O, Thorpe PE, Uhr JW, Vitetta ES: A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624, 1993
44. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr J, Wittes RE, Vitetta ES: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. Blood 85:3457, 1995
45. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr J, Thorpe PE: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052, 1991
46. Uckun F: Immunotoxins for the treatment of leukaemia. Br J Haematol 85:435, 1993
47. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, StetlerStevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES: A phase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88:1188, 1996
48. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blattler WA, Taylor JA, Nadler LM: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood 79:576, 1992
49. Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA: Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma 26:287, 1997
50. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362, 1997
51. 486IL-2) in patient with chronic lymphocytic leukaemia. Lancet 337:1124, 1991
52. 389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91:399, 1998
53. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HAG, Messing E, Crawford ED, Oliff AI, Pastan IH: Phase I clinical study of recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1:57, 1995
54. Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I: B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 88:8616, 1991
55. Kreitman RJ, Wang QC, FitzGerald DJP, Pastan I: Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by Cynomolgus monkeys. Int J Cancer 81:148, 1999
56. Blasinska-Morawiec M, Robak T, Krykowski E, Hellmann A, Urbanska-Rys H: Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine - A report of three cases. Leuk Lymphoma 25:381, 1997
57. Dunn P, Shin LY, Ho YS, Tien HF: Hairy cell leukemia variant. Acta Haematol 94:105, 1995